Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

British pharmaceutical industry is threatened by Labour, says former Party health minister

December 2, 2019 Sales and Marketing British pharmaceuticals, Election 2019, Jeremy Corbyn, Labour Party, NHS

A former Labour Party health minister has said that the British pharmaceutical industry is “under threat” from a Jeremy Corbyn …
News

Roche’s satralizumab shows promise at Phase 3 in neuromyelitis optica spectrum disorder

December 2, 2019 Research and Development, Sales and Marketing Roche, pharma, satralizumab

Roche has presented new data on its interleukin-6 (IL-6) inhibitor satralizumab in the treatment of neuromyelitis optica spectrum disorder (NMOSD), …
News
top_10_image_43

Top Ten most popular articles on Pharmafile.com this week

November 29, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boris Johnson, Jeremy Corbyn, NHS, Opiod, US, opiod crisis

The NHS was featured heavily in the news this week. Jeremy Corbyn revealed documents detailing previous UK-US discussions in which …
News
corbyn_nhs

Corbyn reveals documents showing US-UK meetings on deregulating NHS drug pricing

November 27, 2019 Research and Development, Sales and Marketing Jeremy Corbyn, Labour Party, NHS, US, pharma

Labour Leader Jeremy Corbyn has showed off documents that detail secret trade meetings between the US and UK Governments, where …
News
shutterstock_79370437

New ICER report reveals most cost-effective rheumatoid arthritis therapies

November 27, 2019 Research and Development, Sales and Marketing AbbVie, Eli Lilly, Humira, Olumiant, Pfizer, Rinvoq, Xeljanz, pharma

The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of …
News
celltrion1

Europe approves first subcutaneous version of biosimilar infliximab

November 26, 2019 Manufacturing and Production, Sales and Marketing arthritis, biosimilars, celltrion, infliximab, pharma

The European Commission has chosen to authorise Celltrion Healthcare’s Remsima SC, a biosimilar of infliximab and the first subcutaneous formulation …
News

The coming age of biosimilars

November 25, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biosimilars, feature, pharma

With more and more biosimilars securing approval and the sheer potential value they have to offer for healthcare systems around …
Feature
m-mansuri_370x250px

Sanofi’s head of strategy and business development to retire amid company review

November 25, 2019 Sales and Marketing Bristol Meyers, Gilead, Sanofi, Shell

One of Sanofi’s most senior strategy bosses is set to retire at the end of the month. Muzammil Mansuri, Executive …
News

FDA approves AstraZeneca’s Calquence in chronic lymphoma

November 25, 2019 Sales and Marketing Astrazenaca, Calquence, FDA, Health Canada, leukaemia, oncology

The FDA has approved AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) in the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic …
News
fdaoutsideweb

FDA fast-tracks psilocybin treatment for major depressive disorder

November 25, 2019 Sales and Marketing Controlled Substance Act, FDA, breakthrough therapy, major depressive disorder, psilocybin

The FDA has granted a Breakthrough Therapy designation to the Usona Institute for its trial use of psilocybin in the …
News
novartis_outside_1

Novartis acquires The Medicines Company in a deal worth $9.7 billion

November 25, 2019 Sales and Marketing Novartis, The Medicines Company, pharma

Novartis agreed a $9.7 billion deal to acquire the US-based The Medicines Company, it announced Sunday. The transaction was unanimously …
News
roche__tree

Roche’s Tecentriq combo outclasses Nexavar in unresectable hepatocellular carcinoma

November 25, 2019 Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq

Roche has revealed new Phase 3 data for its immunotherapy drug Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …
News
uk

Scotland leading the UK in life science start-up growth, report reveals

November 20, 2019 Research and Development, Sales and Marketing BioCity, UK, biotech, pharma

A new report published by the life science incubator and business collective BioCity has painted a promising picture of UK …
News
merck-keytruda

Europe approves Keytruda for first-line head and neck squamous cell carcinoma, as a monotherapy or combo

November 20, 2019 Research and Development, Sales and Marketing Cancer, keytruda, pharma

MSD’s top-selling immunotherapy Keytruda (pembrolizumab) has secured another approval from the European Commission, this time in the first-line treatment of …
News
darzalex-product-shot---100mg-vial-2-hr

European Commission approves Genmab’s Darzalex combo in newly diagnosed multiple myeloma

November 20, 2019 Research and Development, Sales and Marketing Europe, Genmab, darzalex, pharma

Genmab’s Darzalex (daratumumab) has secured approval from the European Commission and is now authorised in Europe for the treatment of …
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026